The firm saw an increase in diagnostics solutions sales in the second quarter, particularly within its QuantiFeron and QiaStat-Dx businesses.

The firm anticipates lower-than-previously-expected COVID test sales will be offset by shifts in trade policy and tariff mitigation efforts.

As part of the deal, the company is acquiring a "significant library of potential applications" of the test's exosome-based technology.

Including its COVID-19-related business, the company's second quarter revenues were down 43 percent year over year.

At ADLM, the company provided a preview of its Liaison Nes point-of-care PCR instrument that is complementary to the firm's Liaison Plex syndromic testing system.

Stakeholders suggested that while the FDA rule is dead, updates to LDT regulation are coming, nonetheless, and the industry ...

Danaher subsidiaries Beckman Coulter, Cepheid, and Leica Biosystems will be working together with external partners to focus ...

The South Korean firm said that its CURECA system offers walkaway PCR testing with 24/7 operation without human intervention ...

China's volume-based procurement policy and US tariffs have forced companies with large businesses in China to reset their ...

Some experts believe a technological tipping point is imminent, if not already here, but adoption of point-of-care MDx has ...

Through clinical trials, partnerships, and economic studies, a crop of test developers is trying to prove the value of their ...

The development marks a shift up the value chain for labs and could prove a meaningful revenue stream for providers able to ...